Effect of Ivermectin Metabolites on Mosquito Survival

Summary

This clinical trial will be designed to capture the full duration of mosquito-lethal effect of single dose Ivermectin to aid efforts to characterize metabolites with mosquito-lethal effect. Ivermectin and its metabolites likely have antiparasitic properties against asexual and sexual stage Plasmodium parasites that will be investigated with plasma samples from this study. This is an open-label pharmacokinetic study. Ten healthy participants will be admitted in the inpatient ward to receive a single oral dose of IVM (400 µg/kg). Another 10 healthy participants will be donate blood up to 42 ml each times for up to 3 times. There is no drug administration for these participants. The total duration for each volunteer's participation in the study is approximately 2 months.

Timeline

Start

2019-02-04

Primary completion

2022-04-05

Completion

2022-04-05

Publications

• Results Kobylinski KC, Tipthara P, Wamaket N, Chainarin S, Kullasakboonsri R, Sriwichai P, Phasomkusolsil S, Hanboonkunupakarn B, Jittamala P, Gemmell R, Boyle J, Wrigley S, Steele J, White NJ, Tarning J. Author Correction: Ivermectin metabolites reduce Anopheles survival. Sci Rep. 2024 Oct 24;14(1):25243. doi: 10.1038/s41598-024-76902-z. No abstract available.

Drugs

Indications

No indication recorded.